Drugs in the Pipeline

ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous delivery.

The DISSOLVE I and II trials evaluated the efficacy and safety of 2 different dose levels of SEL-212 in adults 19 years of age and older with chronic refractory gout.

Ulenistamab targets pancreatic adenocarcinoma upregulated factor, a tumor-specific protein.

FORE8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF.

KarXT is an oral, investigational therapy that combines xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist.

Results showed a significantly greater proportion of patients treated with tapinarof cream achieved vIGA-AD success compared with vehicle cream.

The panel reviewed data from the randomized, double-blind, placebo-controlled phase 3 POLARIX trial.

Solanezumab is a humanized monoclonal antibody designed to increase clearance of soluble amyloid beta (Aβ) from the brain by binding to aggregated forms of Aβ.

The table provided is a review of notable updates that occurred in February 2023 for investigational products in development.

The sNDA is supported by data from the phase 3 DINAMO trial, which include patients 10 to less than 18 years of age with type 2 diabetes who are currently receiving metformin, insulin, or both.